Highest-materiality recent filing
Ludwig Enterprises closes $200K convertible note and warrant placement with Alumni Capital LP
Issued $250K convertible promissory note to Alumni Capital LP; maturity May 4, 2026; net proceeds $200K after original issue discount.
CEO Charles T. Todd Jr. resigns effective August 23, 2025; no replacement named yet
Charles T. Todd Jr. resigned as CEO of Ludwig Enterprises, effective August 23, 2025.
Ludwig Enterprises appoints Charles Todd Jr. as CEO and Chairman; auditor changes
Charles Todd Jr., former BioReference EVP who grew revenue from $23M to $1.2B, appointed CEO and Chairman effective April 21, 2025.
Ludwig Enterprises sells Exousia Ai to Marijuana, Inc. for $500K in stock and note
Sold 100% of Exousia Ai to Marijuana, Inc. (MAJI) for $500,000 total consideration.
Ludwig Enterprises acquires mRNA Neuro Panel patent, serotonin assay IP from Nova Mentis
Acquired U.S. Patent Application 18/705375 and related IP for mRNA neuro panel and serotonin assay from Nova Mentis.
Dr. Marvin S. Hausman resigned as CEO effective August 20, 2024; no disagreement with company operations.
Ludwig to rename Revealia, plans 2024 launch of cancer screening test
Majority shareholders approved name change to Revealia, Inc., pending FINRA approval.
Ludwig Enterprises enters $5M equity line and $50K promissory note with institutional investor
Common Stock Purchase Agreement for up to $5,000,000; shares sold at 80% of lowest traded price over six days.
On June 23, 2025, the Board appointed a new independent director, Garth Lees-Rolfe, to hold office until the earlier of the expiration of the term of office, a successor is duly elected and qualified, or the earlier of her death, resignation, disqualification, or removal.
On June 5, 2025, the Board of Directors (the “Board”) of Ludwig Enterprises, Inc. (the “Company”) received a letter of resignation from Dr. Marvin S. Hausman from his position on the Board, Dr. Hausman will remain in his position as Chief Scientific Officer of the Company.
Charles Todd, Jr.. (the “Executive”), who, in conjunction with the execution the Employment Agreement, was appointed as the Company’s Chief Executive Officer
Marvin S. Hausman, M.D. resigned as Chief Executive Officer, effective immediately.
the Board appointed a new Chief Executive Officer, Jose Antonio Reyes, effective immediately.
On November 28, 2023, the Company’s Board of Directors (the “Board”) appointed two new directors to the Board: (1) Marvin Hausman, M.D., the Company’s current Chief Executive Officer; and (2) Scott J. Silverman, the Company’s current Chief Financial Officer.
On November 28, 2023, the Company’s Board of Directors (the “Board”) appointed two new directors to the Board: (1) Marvin Hausman, M.D., the Company’s current Chief Executive Officer; and (2) Scott J. Silverman, the Company’s current Chief Financial Officer.
Scott J. Silverman, who, in conjunction with the execution the CFO Agreement, was appointed as the Company’s Chief Financial Officer
Max materiality 0.75 · Median 0.55 · Most common event leadership